This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bristol Myers' Opdivo+Yervoy Combo Gets FDA Nod for HCC
by Zacks Equity Research
Bristol Myers (BMY) gets FDA approval for the Opdivo and Yervoy combination for the treatment of HCC.
Aduro's (ADRO) Earnings & Revenues Miss Estimates in Q4
by Zacks Equity Research
Aduro (ADRO) incurs wider-than-expected loss in Q4. Revenues too fall short of the mark.
This is Why Merck (MRK) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Bristol-Myers Empliciti Combo Fails in First-Line Myeloma Study
by Zacks Equity Research
Bristol-Myers' (BMY) Empliciti, Revlimid and dexamethasone combination regimen fails to improve progression free survival in first-line multiple myeloma patients.
Simple Secrets Anyone Can Use to Reach Early Retirement - March 10, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Why Is Merck (MRK) Down 4.8% Since Last Earnings Report?
by Zacks Equity Research
Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Idera Completes Recruitment in Late-Stage Melanoma Study
by Zacks Equity Research
Idera (IDRA) closes enrollment in the late-stage ILLUMINATE-301 study, evaluating the combo of tilsotolimod plus Yervoy in patients with anti-PD-1 refractory advanced melanoma.
Pharma Stock Roundup: Trump, Pharma Executives Meeting on Coronavirus, FDA Updates
by Kinjel Shah
Trump asks pharma firms to accelerate development of coronavirus vaccine/treatment. FDA approves Sanofi's (SNY) Sarclisa and Allergan'sa (AGN) Durysta.
Merck (MRK) Stock Moves -1.68%: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $81.58, marking a -1.68% move from the previous day.
The Zacks Analyst Blog Highlights: Merck, Novartis, Mondelez International, ServiceNow and General Dynamics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Novartis, Mondelez International, ServiceNow and General Dynamics
Signs That Your Trading Will Ruin Your Retirement - March 03, 2020
by Zacks Equity Research
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
Merck's Keytruda Improves PFS in Phase III Lymphoma Study
by Zacks Equity Research
Merck's (MRK) Keytruda significantly improves progression-free survival compared with brentuximab vedotin in patients with relapsed or refractory classical Hodgkin Lymphoma (cHL)
Top Analyst Reports for Merck, Novartis & Mondelez
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Merck (MRK), Novartis (NVS) and Mondelez International (MDLZ).
Dow Logs Worst One-Day Slump in History: ETF & Stock Winners
by Sanghamitra Saha
Dow Jones saw the worst single-day slump on Thursday. While inverse Dow Jones ETFs gained considerably, these stocks too were less hurt.
Simple Secrets Anyone Can Use to Reach Early Retirement - February 28, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Esperion (ESPR) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports encouraging fourth-quarter results. The company is set to launch its first drug next month.
Exelixis (EXEL) Beats on Earnings, Misses on Sales in Q4
by Zacks Equity Research
Exelixis' (EXEL) Q4 results are a mixed bag, as earnings beat, while sales marginally miss estimates.
This is Why Merck (MRK) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
The Extreme Risks of Trading Your Own Retirement Assets - February 24, 2020
by Zacks Equity Research
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
Corcept (CORT) Q4 Earnings In-Line with Estimates, Up Y/Y
by Zacks Equity Research
Corcept Therapeutics (CORT) reports in-line earnings in the fourth quarter of 2020.
Pharma Stock Roundup: AZN Reports Q4 Results, NVS, PFE Drugs Get EU Approval
by Kinjel Shah
AstraZeneca's (AZN) Q4 results were disappointing. European Commission approves Novartis (NVS) and Pfizer's (PFE) new drugs.
Moderna (MRNA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Progress of its pipeline candidates is likely to have increased Moderna's (MRNA) operating expenses in the fourth quarter.
Roche's Tecentriq sBLA for Lung Cancer Gets Priority Review
by Kinjel Shah
Roche (RHHBY) gets FDA's priority review status for a sBLA for Tecentriq monotherapy in first-line treatment of certain people with advanced non-small cell lung cancer.
Powerful Proof Anyone Can Invest for an Early Retirement - February 20, 2020
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
NewLink (NLNK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are looking forward to updates on NewLink's (NLNK) merger with Lumos Pharma, when the former releases fourth-quarter 2019 results.